Summary of Consolidated Financial Results [IFRS]
for the First Three Months of the Fiscal Year Ending March 31, 2027

August 7, 2026

Listed company name	:	Sysmex Corporation
Code	:	6869
Listed stock exchanges	:	Tokyo Stock Exchange
URL	:	www.sysmex.co.jp/en
Company representative	:	Iwane Matsui, President
Contact	:	Takuro Minami, Executive Vice President of Corporate Business Administration
Phone	:	078(265)-0500
Scheduled date for dividend payment	:	—
Preparation of supplementary material for quarterly earnings	:	Yes
Holding of earnings announcement	:	Yes

(Unit: Millions of Yen)

1. Results for the First Three Months of the Fiscal Year Ending March 31, 2027

(1) Operating results

(% changes as compared with the corresponding period of the previous fiscal year)

	Net Sales		Operating profit		Profit before tax		Profit	
Three months ended Jun. 30, 2026	130,674	23.6%	14,821	39.5%	14,110	79.2%	8,616	92.5%
Three months ended Jun. 30, 2025	105,731	(5.6)%	10,628	(36.5)%	7,873	(53.6)%	4,476	(59.2)%

	Profit attributable to owners of the parent		Total comprehensive income		Basic earnings per share (Yen)	Diluted earnings per share (Yen)
Three months ended Jun. 30, 2026	8,691	90.9%	15,209	88.7%	14.17	14.17
Three months ended Jun. 30, 2025	4,553	(58.7)%	8,059	(67.3)%	7.30	7.30

(2) Financial condition

	Total assets	Total equity	Equity attributable to owners of the parent	Equity attributable to owners of the parent to total assets
As of Jun. 30, 2026	746,637	486,181	485,581	65.0
As of Mar. 31, 2026	707,532	505,676	505,000	71.4

2. Dividend

	Dividend per share				
	First quarter (Yen)	Second quarter (Yen)	Third quarter (Yen)	Year-end (Yen)	Annual (Yen)
Year ended Mar. 31, 2026	—	19.00	—	19.00	38.00
Year ending Mar. 31, 2027	—				
Year ending Mar. 31, 2027 (Forecast)		20.00	—	20.00	40.00

Note: Revision of dividends forecast for this period: No

3. Financial Forecast for the Year Ending March 31, 2027

(% changes as compared with the corresponding period of the previous fiscal year)

	Net Sales		Operating profit		Profit before tax		Profit attributable to owners of the parent		Basic earnings per share (Yen)
Six months ending Sep. 30, 2026	265,000	14.0%	25,000	(24.1)%	23,000	(23.2)%	15,000	(21.1)%	24.68
Year ending Mar. 31, 2027	545,000	9.0%	60,000	15.8%	56,000	14.2%	37,000	4.4%	60.89

Note: Revision of financial forecast for this period: Yes

4. Other Information

(1) Significant changes in scope of consolidation: Yes
Newly included: One company (Sysmex BioMajesty Co., Ltd)

(2) Changes in accounting policies and accounting estimates
1) Changes in accounting policies required by IFRS: No
2) Other changes in accounting policies: No
3) Changes in accounting estimates: No

(3) Number of outstanding stock (common stock)
1) Number of outstanding stock at the end of each fiscal period (including treasury stock):
629,480,076 shares as of Jun. 30, 2026; 629,480,076 shares as of Mar. 31, 2026
2) Number of treasury stock at the end of each fiscal period:
24,275,357 shares as of Jun. 30, 2026; 7,995,365 shares as of Mar. 31, 2026
3) Average number of outstanding stock for each period (cumulative):
613,223,088 shares for the three months ended Jun. 30, 2026
623,604,502 shares for the three months ended Jun. 30, 2025

Note: The Company has introduced the Executive Compensation BIP Trust and the ESOP Trust. Company shares held by these trusts are included in treasury stock and are excluded from calculations of the number of treasury stock at the end of the fiscal period and the average number of outstanding stock for the period.

* Review of the accompanying quarterly consolidated financial statements by a certified public accountant or auditing firm: Yes

* Explanation regarding the appropriate use of financial forecast and other information

1. The forecasts and future projections contained herein have been prepared on the basis of rational decisions given the information available as of the date of announcement of this document. These forecasts do not represent a commitment by the Company, and actual performance may differ substantially from forecasts for a variety of reasons. Please refer to “3) Consolidated financial forecast” within “1. Qualitative information on quarterly financial results” on page 4 of the attachment to this document for cautionary statements concerning the conditions and performance forecasts that serve as the basis for these forecasts.
2. Supplementary financial materials (in Japanese and English) will be posted on the Sysmex website on Friday, August 7, 2026.

Content of Supplementary Materials

1. Qualitative information on quarterly financial results

Future-related information contained in the text below is based on the judgement as of the end of the fiscal period under review.

1) Operating performance analysis

The Group's consolidated financial results for the first quarter of the fiscal year ending March 31, 2027 are as follows.

Net sales by destination

		Three months ended June 30, 2025		Three months ended June 30, 2026		YoY (Previous period = 100)
		Amount (Millions of yen)	Percentage of total (%)	Amount (Millions of yen)	Percentage of total (%)	
Japan		11,011	10.4	17,391	13.3	157.9
	Americas	30,205	28.6	41,966	32.1	138.9
	EMEA (Europe, the Middle East, and Africa)	35,151	33.2	44,125	33.8	125.5
	China	17,272	16.4	13,388	10.2	77.5
	AP (Asia Pacific)	12,090	11.4	13,803	10.6	114.2
Overseas subtotal		94,720	89.6	113,283	86.7	119.6
Total		105,731	100.0	130,674	100.0	123.6

In Japan, sales in the clinical chemistry field increased following the start of business operations by Sysmex BioMajesty Co., Ltd., acquired from JEOL Ltd. As a result, sales in Japan up 57.9% year on year, to ¥17,391 million. The ratio of sales in Japan increased 2.9 percentage points, to 13.3%.

Overseas, sales of hematology instruments, reagents, and maintenance services increased. This factor, coupled with depreciation of the yen in foreign exchange markets, caused overseas sales to up 19.6%, to ¥113,283 million. The overseas sales ratio down 2.9 percentage points, to 86.7%.

Selling, general and administrative (SG&A) expenses totaled ¥42,613 million, up 11.3% year on year, mainly due to increases in personnel accompanying the expansion of business. R&D expenses came to ¥7,211 million, up 12.5%.

As a result, on a consolidated basis for the first quarter of the fiscal year ending March 31, 2027, net sales amounted to ¥130,674 million (up 23.6% year on year), operating profit was ¥14,821 million (up 39.5%), profit before tax was ¥14,110 million (up 79.2%), and profit attributable to owners of the parent totaled ¥8,691 million (up 90.9%).

Performance by segment

(1) Headquarters

In Japan, sales in the clinical chemistry field increased following the start of business operations by Sysmex BioMajesty Co., Ltd. In addition, sales of reagents and maintenance services in the hematology field rose in South Korea. As a result, segment sales rose 49.6% year on year, to ¥25,427 million.

On the profit front, higher net sales led to an increase in gross profit, bolstering segment profit (operating profit) 189.1% year on year, to ¥6,437 million.

(2) Americas RHQ

In North America, sales of instruments, reagents and maintenance services in the hematology field increased. In Central and South America, sales of hematology instruments and reagents increased, as did sales of urinalysis reagents. As a result, segment sales rose 37.2% year on year, to ¥39,211 million.

On the profit front, although SG&A expenses increased, higher net sales and an improvement in the cost of sales ratio pushed up segment profit (operating profit) 223.7% year on year, to ¥2,593 million.

(3) EMEA RHQ

Sales of instruments and reagents in the hematology, hemostasis and urinalysis fields increased, mainly in European countries. As a result, segment sales rose 24.7% year on year, to ¥42,378 million.

On the profit front, although SG&A expenses increased, but the higher gross profit on increased sales boosted segment profit (operating profit) 63.7% year on year, to ¥3,705 million.

(4) China RHQ

Sales of instruments, reagents and maintenance services in the hemostasis field decreased, as did sales of instruments in the hematology field. As a result, segment sales fell 22.6% year on year, to ¥13,343 million.

On the profit front, although SG&A expenses decreased, lower sales caused gross profit to decline. Consequently, segment profit (operating profit) fell 42.9% year on year, to ¥954 million.

(5) AP RHQ

Sales of reagents in the hematology and hemostasis fields increased, mainly in the Indian market. As a result, segment sales rose 15.5% year on year, to ¥10,313 million.

On the profit front, despite higher net sales, a deterioration in the cost of sales ratio and an increase in SG&A expenses caused segment profit (operating profit) to fall 31.0% year on year, to ¥1,059 million.

2) Financial conditions analysis

(1) Financial conditions

As of June 30, 2026, total assets amounted to ¥746,637 million, a increase of ¥39,105 million compared with March 31, 2026. This increase was due chiefly to rises of ¥29,517 million in cash and cash equivalents and ¥11,221 million in inventories.

Total liabilities increased by ¥58,599 million from March 31, 2026, to ¥260,455 million. This rise was mainly because of a ¥49,821 million increase in long-term loans payable.

Total equity decreased by ¥19,494 million from March 31, 2026, to ¥486,181 million. This was mainly owing to a decrease of ¥22,865 million resulting from the acquisition of treasury stock. As a result, the equity attributable to owners of the parent to total assets down 6.4 percentage points, from 71.4% as of March 31, 2026, to 65.0%.

(2) Cash flows

As of June 30, 2026, cash and cash equivalents amounted to ¥113,634 million, up ¥29,517 million from March 31, 2026.

Cash flows from various activities during the first quarter are described in more detail below.

(Cash flows from operating activities)

Net cash provided by operating activities was ¥35,595 million (up ¥26,103 million from the first three months of the previous fiscal year). This was due mainly to profit before tax of ¥14,110 million (up ¥6,237 million year on year), depreciation and amortization of ¥12,028 million (up ¥1,265 million), a decrease in trade receivables of ¥17,687 million (down ¥1,434 million), and a decrease in accrued bonuses of ¥7,431 million (down ¥583 million).

(Cash flows from investing activities)

Net cash used in investing activities was ¥18,595 million (up ¥6,492 million). This was attributable chiefly to purchases of property, plant and equipment of ¥6,314 million (up ¥623 million year on year), purchases of intangible assets of ¥3,771 million (down ¥2,656 million), and acquisitions of subsidiaries or other businesses of ¥7,838 million (up ¥7,838 million).

(Cash flows from financing activities)

Net cash provided by financing activities was ¥12,032 million (¥13,301 million used in the previous period). This was due mainly to proceeds from long-term loans payable of ¥50,000 million (up ¥50,000 million year on year), purchases of treasury shares of ¥22,883 million (up ¥22,883 million), and dividends paid of ¥11,808 million (up ¥1,207 million).

3) Consolidated financial forecast

For the Company's consolidated financial forecasts for the Six Months Ended September 30, 2026 and the full fiscal year, please refer to Announcement Regarding Revision of Financial Forecast for the Six Months Ending September 30, 2026, and Revision of Full-Year Financial Forecast for the Fiscal Year Ending March 31, 2027, announced today (August 7, 2026).

2. Condensed quarterly consolidated financial statements and notes

1) Condensed quarterly consolidated statement of financial position

(Unit: Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Assets		
Current assets		
Cash and cash equivalents	84,117	113,634
Trade and other receivables	168,783	158,791
Inventories	95,613	106,835
Other short-term financial assets	775	635
Income taxes receivable	8,757	5,973
Other current assets	30,559	30,494
Total current assets	388,606	416,365
Non-current assets		
Property, plant and equipment	150,396	154,448
Goodwill	4,138	8,730
Intangible assets	93,173	92,659
Investments accounted for using the equity method	150	454
Trade and other receivables	34,756	36,979
Other long-term financial assets	14,025	14,654
Asset for retirement benefits	0	30
Other non-current assets	6,643	6,509
Deferred tax assets	15,641	15,804
Total non-current assets	318,925	330,272
Total assets	707,532	746,637

(Unit: Millions of yen)

	As of March 31, 2026	As of June 30, 2026
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	34,116	32,991
Lease liabilities	9,555	10,176
Other current financial liabilities	1,316	6,201
Income taxes payable	2,980	3,238
Provisions	1,342	1,446
Contract liabilities	20,770	20,045
Accrued expenses	22,610	27,837
Accrued bonuses	14,976	7,829
Other current liabilities	11,591	12,802
Total current liabilities	119,259	122,568
Non-current liabilities		
Long-term loans payable	31,646	81,468
Lease liabilities	29,280	31,881
Other non-current financial liabilities	35	30
Liability for retirement benefits	2,238	3,078
Provisions	1,307	1,316
Other non-current liabilities	12,198	13,729
Deferred tax liabilities	5,889	6,382
Total non-current liabilities	82,596	137,887
Total liabilities	201,856	260,455
Equity		
Equity attributable to owners of the parent		
Capital stock	14,898	14,898
Capital surplus	21,114	21,084
Retained earnings	416,253	413,136
Treasury stock	(15,501)	(38,366)
Other components of equity	68,236	74,829
Total equity attributable to owners of the parent	505,000	485,581
Non-controlling interests	675	599
Total equity	505,676	486,181
Total liabilities and equity	707,532	746,637

2) Condensed quarterly consolidated statement of income

(Unit: Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Net sales	105,731	130,674
Cost of sales	51,267	64,364
Gross profit	54,463	66,310
Selling, general and administrative expenses	38,296	42,613
Research and development expenses	6,407	7,211
Other operating income	1,084	1,064
Other operating expenses	215	2,728
Operating profit	10,628	14,821
Financial income	198	245
Financial expenses	909	1,272
Share of profit (loss) of associates accounted for using the equity method	(534)	(477)
Foreign exchange gain (loss)	(1,508)	793
Profit before tax	7,873	14,110
Income taxes expenses	3,397	5,494
Profit	4,476	8,616
Profit attributable to		
Owners of the parent	4,553	8,691
Non-controlling interests	(76)	(75)
Profit	4,476	8,616

(Unit: Yen)

Earnings per share		
Basic	7.30	14.17
Diluted	7.30	14.17

3) Condensed quarterly consolidated statement of comprehensive income

(Unit: Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Profit	4,476	8,616
Other comprehensive income		
Items that will not be reclassified subsequently to profit or loss		
Net gain (loss) on financial assets measured at fair value through other comprehensive income	154	6
Total	154	6
Items that may be reclassified subsequently to profit or loss		
Exchange differences on translation of foreign operations	3,422	6,580
Share of other comprehensive income of investments accounted for using the equity method	5	6
Total	3,428	6,586
Total other comprehensive income	3,582	6,592
Comprehensive income	8,059	15,209
Comprehensive income attributable to		
Owners of the parent	8,135	15,284
Non-controlling interests	(76)	(75)
Comprehensive income	8,059	15,209

4) Condensed quarterly consolidated statement of changes in equity

Three months ended June 30, 2025

(Unit: Millions of yen)

	Equity attributable to owners of the parent						Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity	Total		
As of April 1, 2025	14,887	20,960	402,820	(12,318)	37,425	463,776	758	464,534
Profit			4,553			4,553	(76)	4,476
Other comprehensive income					3,582	3,582		3,582
Comprehensive income	—	—	4,553	—	3,582	8,135	(76)	8,059
Exercise of warrants	10	6				16		16
Share-based payment transactions		13				13		13
Cash dividends			(10,601)			(10,601)		(10,601)
Purchase of treasury stock						—		—
Disposal of treasury stock		(9)		9		—		—
Transfer to retained earnings			(41)		41	—		—
Total transactions with the owners	10	9	(10,642)	9	41	(10,571)	—	(10,571)
As of June 30, 2025	14,898	20,970	396,731	(12,309)	41,050	461,340	681	462,022

Three months ended June 30, 2026

(Unit: Millions of yen)

	Equity attributable to owners of the parent						Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity	Total		
As of April 1, 2026	14,898	21,114	416,253	(15,501)	68,236	505,000	675	505,676
Profit			8,691			8,691	(75)	8,616
Other comprehensive income					6,592	6,592		6,592
Comprehensive income	—	—	8,691	—	6,592	15,284	(75)	15,209
Exercise of warrants						—		—
Share-based payment transactions		(20)				(20)		(20)
Cash dividends			(11,808)			(11,808)		(11,808)
Purchase of treasury stock				(22,883)		(22,883)		(22,883)
Disposal of treasury stock		(8)		18		9		9
Transfer to retained earnings						—		—
Total transactions with the owners	—	(29)	(11,808)	(22,865)	—	(34,703)	—	(34,703)
As of June 30, 2026	14,898	21,084	413,136	(38,366)	74,829	485,581	599	486,181

5) Condensed quarterly consolidated statement of cash flows

(Unit: Millions of yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Cash flows from operating activities		
Profit before tax	7,873	14,110
Depreciation and amortization	10,762	12,028
Share of loss (profit) of associates accounted for using the equity method	534	477
Loss on retirement of non-current assets	57	148
Decrease (increase) in trade receivable	19,122	17,687
Decrease (increase) in advance payments	(794)	(1,167)
Decrease (increase) in inventories	(4,757)	(4,707)
Increase (decrease) in trade payable	(2,016)	(765)
Increase (decrease) in accounts payable–other	(608)	293
Increase (decrease) in contract liabilities	(937)	(776)
Increase (decrease) in accrued expenses	(827)	4,686
Decrease/increase in consumption taxes receivable/payable	1,898	4,755
Increase (decrease) in accrued bonuses	(8,014)	(7,431)
Other－net	(784)	(1,898)
Subtotal	21,507	37,440
Interest and dividend received	168	252
Interest paid	(540)	(574)
Income taxes paid	(11,643)	(1,523)
Net cash provided by (used in) operating activities	9,492	35,595
Cash flows from investing activities		
Purchases of property, plant and equipment	(5,691)	(6,314)
Purchases of intangible assets	(6,427)	(3,771)
Payments resulting in an increase in long-term prepaid expenses	(165)	(18)
Payments into time deposits	(19)	(0)
Proceeds from withdrawal of time deposits	434	239
Purchase of other financial assets	(49)	(261)
Acquisition of investments accounted for using the equity method	－	(350)
Acquisitions of subsidiaries or other businesses	－	(7,838)
Other－net	(182)	(280)
Net cash provided by (used in) investing activities	(12,102)	(18,595)
Cash flows from financing activities		
Proceeds from long-term loans payable	－	50,000
Repayments of long-term loans payable	(178)	(178)
Exercise of warrants	16	－
Purchase of treasury shares	－	(22,883)
Dividends paid	(10,601)	(11,808)
Repayments of lease liabilities	(2,547)	(3,107)
Other－net	9	9
Net cash provided by (used in) financing activities	(13,301)	12,032
Effects of exchange rate changes on cash and cash equivalents	817	485
Net increase (decrease) in cash and cash equivalents	(15,094)	29,517
Cash and cash equivalents at the beginning of the term	89,570	84,117
Cash and cash equivalents at the end of the term	74,476	113,634

6) Notes to the condensed quarterly consolidated financial statements

1. Key considerations on the basis for the preparation of condensed quarterly consolidated financial statements

The condensed quarterly consolidated financial statements have been prepared in accordance with Article 5, Paragraph 2 of the Standards for Preparation of Quarterly Consolidated Financial Statements, etc. of Tokyo Stock Exchange, Inc. (However, in accordance with Article 5, Paragraph 5 of the Standards for the Preparation of Quarterly Financial Statements, some disclosures in International Accounting Standard No. 34 "Interim Financial Reporting" are omitted.)

2. Notes related to the going concern assumption

Not applicable

3. Segment information

1) Overview of reportable segments

The reportable segments of the Company and its subsidiaries (the Group) are the constituent business units of the Group for which separate financial data are available and that are examined on a regular basis for the purpose of enabling the Managing Board to allocate managerial resources and evaluate results of operations.

The Group is primarily engaged in the manufacture and sale of diagnostic instruments and reagents. These businesses are conducted in Japan and East Asia by Sysmex and in the Americas, EMEA, China, and the Asia Pacific by regional headquarters established therein. These companies formulate comprehensive strategies tailored to regional characteristics and conduct business activities accordingly. Some overseas subsidiaries are managed by Sysmex depending on the nature of their business.

The five managing company-specific segments are "Headquarters," "Americas RHQ," "EMEA RHQ," "China RHQ," and "AP RHQ."

The companies included in these reportable segments are outlined below.

Reportable segments	Companies included in the reportable segments
Headquarters	Sysmex Corporation, Sysmex RA Co., Ltd., 13 other domestic subsidiaries, Oxford Gene Technology IP Limited, Sysmex Partec GmbH, Sysmex Korea Co., Ltd., 11 other overseas subsidiaries
Americas RHQ	Sysmex America, Inc., Sysmex Reagents America, Inc., Sysmex do Brasil Industria e Comercio Ltda., five other subsidiaries in the Americas
EMEA RHQ	Sysmex Europe SE, Sysmex Deutschland GmbH, Sysmex UK Limited, Sysmex France S.A.S., 25 other subsidiaries in the EMEA region
China RHQ	Sysmex Shanghai ltd., Jinan Sysmex Medical Electronics Co., Ltd., two other subsidiaries in China
AP RHQ	Sysmex Asia Pacific Pte Ltd., Sysmex India Pvt. Ltd., nine other subsidiaries in the Asia Pacific region

2) Segment profit and operating results

Profit and operating results from continuing operations by reportable segment of the Group are as follows;

Intersegment sales are determined based on market prices or costs of goods manufactured.

Accounting policies of reporting segments are consistent with the Group's accounting policies indicated in the consolidated financial statements for the previous fiscal year.

Three months ended June 30, 2025

(Unit: Millions of yen)

	Reportable segment						Adjustments (Note 1)	Consolidated (Note 2)
	Head-quarters	Americas RHQ	EMEA RHQ	China RHQ	AP RHQ	Total		
Sales								
Sales to external customers	17,001	28,579	33,982	17,235	8,931	105,731	—	105,731
Intersegment sales	26,712	8	109	48	10	26,889	(26,889)	—
Total	43,713	28,588	34,092	17,283	8,942	132,620	(26,889)	105,731
Segment profit (loss)	2,227	801	2,263	1,672	1,535	8,499	2,129	10,628
Financial income	—	—	—	—	—	—	—	198
Financial expenses	—	—	—	—	—	—	—	909
Share of profit (loss) of associates accounted for using the equity method	—	—	—	—	—	—	—	(534)
Foreign exchange gain (loss)	—	—	—	—	—	—	—	(1,508)
Profit before tax	—	—	—	—	—	—	—	7,873
Income taxes expenses	—	—	—	—	—	—	—	3,397
Profit	—	—	—	—	—	—	—	4,476

Notes:

1. Segment profit (loss) adjustments of ¥2,129 million include ¥2,222 million for the unrealized gains on inventories and negative ¥93 million for the unrealized gains on non-current assets.
2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed quarterly consolidated statement of income.

Three months ended June 30, 2026

(Unit: Millions of yen)

	Reportable segment						Adjustments (Note 1)	Consolidated (Note 2)
	Head-quarters	Americas RHQ	EMEA RHQ	China RHQ	AP RHQ	Total		
Sales								
Sales to external customers	25,427	39,211	42,378	13,343	10,313	130,674	—	130,674
Intersegment sales	27,150	2	222	98	11	27,485	(27,485)	—
Total	52,577	39,214	42,601	13,442	10,325	158,160	(27,485)	130,674
Segment profit (loss)	6,437	2,593	3,705	954	1,059	14,750	71	14,821
Financial income	—	—	—	—	—	—	—	245
Financial expenses	—	—	—	—	—	—	—	1,272
Share of profit (loss) of associates accounted for using the equity method	—	—	—	—	—	—	—	(477)
Foreign exchange gain (loss)	—	—	—	—	—	—	—	793
Profit before tax	—	—	—	—	—	—	—	14,110
Income taxes expenses	—	—	—	—	—	—	—	5,494
Profit	—	—	—	—	—	—	—	8,616

Notes:

1. Segment profit (loss) adjustments of ¥71 million include ¥628 million for the unrealized gains on inventories and negative ¥557 million for the unrealized gains on non-current assets.
2. Segment profit (loss) is adjusted to coincide with operating profit in the condensed quarterly consolidated statement of income.